Wockhardt Shifts Focus to Novel Antibiotics and Biosimilars

Wockhardt is pivoting from generics to novel antibiotics and biosimilars, targeting a 10-year market exclusivity. Its in-house antibiotic, Zaynich, has shown promising results, with FDA approval expected by 2026. The company also plans to expand into diabetes and obesity drugs while exiting US generics to boost profitability and focus on innovation-driven growth.